Coloplast raises prices to offset energy cost spikes
Increasing energy uncertainty and prices are affecting the Danish medtech company, which is mitigating the consequences by raising its product prices, among other things.
by ulrich quistgaard, translated by daniel pedersen
Like everybody else, Coloplast is impacted by higher prices on both raw materials and freight, but in particular, the current energy prices are becoming a headache for the Danish medtech firm’s chief financial officer, Anders Lonning-Skovgaard.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.